Summit Therapeutics (SMMT) Change in Accured Expenses (2019 - 2026)

Summit Therapeutics' Change in Accured Expenses history runs 8 years deep, the most recent figure standing at -$7.9 million for Q1 2026.

• Quarterly Change in Accured Expenses fell 3.48% year-over-year to -$7.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.7 million (up 94.29% YoY) and the FY2025 annual result came in at $12.9 million, up 8.85% from the prior year.
• Change in Accured Expenses was -$7.9 million for Q1 2026 at Summit Therapeutics, down from $12.8 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $14.0 million in Q2 2025 and bottomed at -$7.9 million in Q1 2026.
• A 5-year average of $1.1 million and a median of $202000.0 in 2024 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2024 — Change in Accured Expenses surged 2120.0% — and 2025, when it plunged 3227.72%.
• Summit Therapeutics' Change in Accured Expenses stood at -$3.2 million in 2022, then jumped by 159.54% to $1.9 million in 2023, then jumped by 506.54% to $11.6 million in 2024, then rose by 10.45% to $12.8 million in 2025, then slumped by 161.36% to -$7.9 million in 2026.
• Business Quant data shows SMMT's Change in Accured Expenses at -$7.9 million in Q1 2026, $12.8 million in Q4 2025, and -$6.3 million in Q3 2025.